San Francisco — Invitrogen began 2005 much like it ended 2004 — with another acquisition.

The company on Monday announced an agreement to pay $60 million in cash to acquire South San Francisco, Calif.-based Zymed Laboratories, an early-stage immunoassay reagent company that is projected to bring in revenues of $15 million in 2005, and another $22 million in 2006.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.